Tekmira ‘s President and CEO, said:. We are very pleased to complete the ApoB SNALP Phase 1 clinical study ApoB SNALP report was good with no liver toxicity tolerated in any of the items, and we observed some encouraging indications of RNAi drug activity we have a won considerable amount of very valuable information and insights, and at this time we believe it is advisable study study and focus our efforts on an improved ApoB SNALP product candidate. With our extensive experience and understanding of siRNA immune stimulation mediated, we are confident that we modify the siRNA payload this these unexpected side effects is why we will concentrate on the development a new ApoB siRNA in the next generation SNALP higher power clearly higher power and we will be willing to continue clinical development of this year, added Dr..
ApoB SNALP is formed production of apolipoprotein production of apolipoprotein B , a protein in the liver, key role in central role in cholesterol metabolism product.
Tekmira remains on track with its second product candidate, PLK1 SNALP to an Investigational New Drug application, a phase 1 study in the second half of the year to submit to initiate PLK1 PLK1 SNALP is being developed as a treatment for cancer and Tekmira scientists SNALP formulations at distal tumors outside of the liver directed developed shown was to an inhibition of tumor growth and prolonged survival time of the treated animals. Importantly, PLK1 SNALP was well tolerated and the results confirmed the efficacy that silencing silencing PLK1 via RNA interference.. (more…)
The present results suggest that dual – task slowing as eg in this driving situation is time of day time of day with the largest slowdown in the early morning hours. Writes writes: In addition to drowsiness, a combination of slowed reactions and impaired central efficiency might contribute to an impairment of performance and a higher risk of traffic accidents in the early morning hours. .. This results in a recent study that shows that even the practiced easy task vehicle braking is subject to dual-task slowing build. When watching the car brake in front of you while processing another stimulus concurrently the braking response The slowed down considerably.
While it was originally hoped that this non-invasive test could even replace invasive coronary angiography, it some years several years that this is is not the case.. Different processing stages.the early morning Multitasking seems to come easier for some and is virtually impossible for others but new research shows that it is difficult for all in the late night and early morning.
The controversial study by JM Miller and colleagues :2324-2336) is the first multi-center study of 64-slice CT angiography. While the results were mainly in agreement with the previous single-center studies and showed good accuracy in general, the negative predictive value was slightly lower . This raises the question of whether the technique actually very accurate without coronary stenosis, when used in clinical routine and in multiple locations.
The CT imaging techniques have evolved very rapidly and in recent years the use of CT image coronary arteries has been growing fast. (more…)
Most people with sedentary office work can return to work four to six weeks after surgery, but those with physically demanding jobs longer longer as a rule.
These data were presented today. Zoe Arvanitakis and David Bennett, co-principal investigators, Rush Alzheimer’s Disease Center for Neurological Sciences, Rush University Medical Center, the American Academy of Neurology meeting in Boston, Massachusetts.. Ceregene presents interim report Phase 1 clinical data CERE-110 for the treatment of Alzheimer’s diseaseCeregene, today announced preliminary clinical data from a Phase 1 trial of CERE-110, developed a gene therapy product nerve growth factor nerve growth factor for the treatment of Alzheimer’s disease. After one year follow-up, the results for the six patients who received CERE-110 in a single administration of a single administration the therapy was well tolerated, and resulted in a preliminary analysis that potential therapy, reduce reduce by cognitive skills and increase your metabolism in at the brain. (more…)
Cell Genesys is on the development and commercialization of novel biological therapies for patients with cancer. The company is currently pursuing two clinical stage product platforms – GVAX cancer immunotherapies and oncolytic virus therapies. Ongoing clinical trials are Phase 3 trials of GVAX immunotherapy for prostate cancer, Phase 2 trials. GVAX immunotherapy for pancreatic cancer and leukemia , and a Phase 1 trial of CG0070 oncolytic virus therapy for bladder cancer Cell Genesys its former subsidiary hold any interest in its former subsidiary, Ceregene, to develop gene therapies for neurodegenerative diseases.
We look not 100 % resistance, but the parasite is much less susceptible to artemisinin than we are used to, when used with other drugs in combination, we can still cure malaria, but it takes a few days longer, ‘Arjen Dondorp led the study, the Telegraph reports (Leach.. This information was of globalhealth.org courtesy of the Henry J. Kaiser Family Foundation you can view the entire Kaiser Daily Global Health Policy Report, search the archives and sign up for e-mail delivery of global health. (more…)